Current management of FECD remains largely palliative, relying on hypertonic saline drops and ointments to mitigate corneal edema. While surgical interventions like Descemet Membrane Endothelial Keratoplasty have improved outcomes, these procedures do not address the progressive loss of endothelial cells. With approximately 19 million prevalent cases identified across major markets in 2025—including 6.6 million in the United States alone—the clinical need for non-surgical, regenerative treatments has become a primary focus for pharmaceutical developers.

Several emerging candidates are currently navigating clinical trials to fill this gap. Kowa Pharmaceuticals is evaluating Ripasudil, a ROCK inhibitor, while Trefoil Therapeutics is advancing TTHX1114, an engineered growth factor aimed at promoting corneal regeneration. Meanwhile, a collaboration between Santen and ActualEyes is testing the mTOR inhibitor STN1010904 to prevent the formation of guttae and reduce cell apoptosis. As these therapies mature, they are expected to shift the standard of care from symptom management to active disease modification, creating new opportunities for medical innovation through 2036.